Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats
- PMID: 18582458
- DOI: 10.1016/j.ejphar.2008.06.019
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats
Abstract
Aldosterone itself has been reported to participate in mediating renal injury, and it was confirmed that the aldosterone synthase CYP11B2 gene, protein, and aldosterone production are locally present in the kidney. To test the hypothesis that a mineralocorticoid receptor antagonist might ameliorate diabetic nephropathy and the inhibition of renal CYP11B2 expression might be associated with these renoprotective effects, spironolactone (50 mg/kg/day) was administered by gavage to uninephrectomized diabetic rats for 3 weeks. Streptozotocin (55 mg/kg, i.v.) significantly increased urinary protein excretion and collagen deposition in glomerular and tubulointerstitial areas in the kidney, which were attenuated by spironolactone treatment. RT-PCR and Western blot analysis revealed that the expression of mRNA for collagen I/IV, transforming growth factor-beta, NADPH oxidase and mineralocorticoid receptor and the mineralocorticoid receptor protein in the kidney was enhanced in the uninephrectomized diabetic rat kidney and that the overexpression of these molecules was suppressed by spironolactone. Renal angiotensin converting enzyme was activated and overexpressed in diabetic rats, and spironolactone inhibited these changes. We demonstrated that spironolactone prevented the streptozotocin-induced increase in the renal CYP11B2 mRNA content. Controlling blood glucose level with insulin also attenuated the renal expression of mRNA for CYP11B2. On the other hand, the treatment of spironolactone in the present study did not affect blood glucose level or blood pressure in uninephrectomized streptozotocin-induced diabetic rats. These results suggest that spironolactone exerted renoprotective effects in uninephrectomized streptozotocin-induced diabetic rats and inhibited local renin-angiotensin-aldosterone system, such as the ACE expression and the hyperglycemia-induced overexpression of CYP11B2, in the kidney.
Similar articles
-
Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.Clin Exp Pharmacol Physiol. 2010 Nov;37(11):1064-70. doi: 10.1111/j.1440-1681.2010.05436.x. Clin Exp Pharmacol Physiol. 2010. PMID: 20678154
-
L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.Hypertens Res. 2011 Apr;34(4):521-9. doi: 10.1038/hr.2010.279. Epub 2011 Jan 27. Hypertens Res. 2011. PMID: 21270815
-
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.Eur J Pharmacol. 2006 Nov 7;549(1-3):124-32. doi: 10.1016/j.ejphar.2006.08.036. Epub 2006 Aug 30. Eur J Pharmacol. 2006. PMID: 16979161
-
The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.Dan Med Bull. 2011 Apr;58(4):B4265. Dan Med Bull. 2011. PMID: 21466768 Review.
-
Induction of cardiac fibrosis by aldosterone.J Mol Cell Cardiol. 2000 Jun;32(6):865-79. doi: 10.1006/jmcc.2000.1129. J Mol Cell Cardiol. 2000. PMID: 10888242 Review.
Cited by
-
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.Pediatr Nephrol. 2009 Dec;24(12):2301-7. doi: 10.1007/s00467-009-1176-z. Epub 2009 Apr 4. Pediatr Nephrol. 2009. PMID: 19347366 Review.
-
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Cardiovasc Diabetol. 2017 May 16;16(1):65. doi: 10.1186/s12933-017-0547-1. Cardiovasc Diabetol. 2017. PMID: 28511711 Free PMC article. Review.
-
Targeting NOX enzymes in pulmonary fibrosis.Cell Mol Life Sci. 2012 Jul;69(14):2365-71. doi: 10.1007/s00018-012-1012-7. Epub 2012 May 23. Cell Mol Life Sci. 2012. PMID: 22618245 Free PMC article. Review.
-
Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.PLoS One. 2012;7(6):e39938. doi: 10.1371/journal.pone.0039938. Epub 2012 Jun 28. PLoS One. 2012. PMID: 22761931 Free PMC article.
-
Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats.Diabetes Metab J. 2012 Apr;36(2):128-35. doi: 10.4093/dmj.2012.36.2.128. Epub 2012 Apr 17. Diabetes Metab J. 2012. PMID: 22540049 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous